These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 26547678)

  • 41. Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions.
    Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
    Stroke; 2017 Sep; 48(9):2457-2463. PubMed ID: 28775134
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of Anti-factor Xa Activity Among Three Different Factor Xa Inhibitors in Non-valvular Atrial Fibrillation Patients with Renal Impairment.
    Tobe A; Osanai H; Tanaka A; Sakaguchi T; Kambara T; Nakashima Y; Asano H; Ishii H; Ajioka M; Murohara T
    Clin Drug Investig; 2020 Jun; 40(6):567-573. PubMed ID: 32314297
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Management of Elective Surgery and Emergent Bleeding with Direct Oral Anticoagulants.
    Kaatz S; Mahan CE; Nakhle A; Gunasekaran K; Ali M; Lavender R; Paje DG
    Curr Cardiol Rep; 2017 Oct; 19(12):124. PubMed ID: 29064044
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
    Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS
    Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
    Eriksson BI; Quinlan DJ; Eikelboom JW
    Annu Rev Med; 2011; 62():41-57. PubMed ID: 21226611
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism.
    Kimpton M; Carrier M
    Expert Opin Drug Saf; 2019 Apr; 18(4):313-320. PubMed ID: 30925842
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of direct oral anticoagulants-associated bleeding in the trauma patient.
    von Heymann C; Rosenthal C; Kaufner L; Sander M
    Curr Opin Anaesthesiol; 2016 Apr; 29(2):220-8. PubMed ID: 26934279
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Direct oral anticoagulants: Current indications and unmet needs in the treatment of venous thromboembolism.
    Bertoletti L; Ollier E; Duvillard C; Delavenne X; Beyens MN; De Magalhaes E; Bellet F; Basset T; Mismetti P; Laporte S
    Pharmacol Res; 2017 Apr; 118():33-42. PubMed ID: 27350265
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
    Arepally GM; Ortel TL
    Annu Rev Med; 2015; 66():241-53. PubMed ID: 25587651
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antidotes to non-vitamin K oral anticoagulants: necessary or not?
    Proietti M; Lip GY
    Expert Opin Pharmacother; 2015; 16(11):1573-6. PubMed ID: 26077323
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Role of New Oral Anticoagulants (NOACs) in Cancer Patients.
    Ravikumar R; Lim CS; Davies AH
    Adv Exp Med Biol; 2017; 906():137-148. PubMed ID: 27620312
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin for Patients With Left Ventricular Thrombus: A Systematic Review and Meta-Analysis.
    Gue YX; Spinthakis N; Egred M; Gorog DA; Farag M
    Am J Cardiol; 2021 Mar; 142():147-151. PubMed ID: 33359200
    [No Abstract]   [Full Text] [Related]  

  • 53. Direct oral anticoagulants (DOACs).
    Vazquez S; Rondina MT
    Vasc Med; 2015 Dec; 20(6):575-7. PubMed ID: 26285587
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations.
    van Es N; Büller HR
    Hematology Am Soc Hematol Educ Program; 2015; 2015():125-31. PubMed ID: 26637711
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Management of bleeding in patients treated with direct oral anticoagulants.
    Levi M
    Crit Care; 2016 Aug; 20():249. PubMed ID: 27543264
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Practical management of rivaroxaban for the treatment of venous thromboembolism.
    Imberti D; Benedetti R
    Clin Appl Thromb Hemost; 2015 May; 21(4):309-18. PubMed ID: 24057396
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.
    Sardar P; Chatterjee S; Lavie CJ; Giri JS; Ghosh J; Mukherjee D; Lip GY
    Int J Cardiol; 2015 Jan; 179():279-87. PubMed ID: 25464465
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Novel oral anticoagulants--issues in clinical practice].
    Hohmann C; Neumann-Haefelin T; Radziwill R; Benöhr P
    Med Monatsschr Pharm; 2015 Oct; 38(10):374-85; quiz 387-8. PubMed ID: 26731855
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism.
    Fontana P; Goldhaber SZ; Bounameaux H
    Eur Heart J; 2014 Jul; 35(28):1836-43. PubMed ID: 24510637
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.